ESTRADERM Drug Patent Profile

Which patents cover Estraderm, and when can generic versions of Estraderm launch?

Estraderm is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in ESTRADERM is estradiol. There are seventy-five drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the estradiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Estraderm

A generic version of ESTRADERM was approved as estradiol by BARR LABS INC on October 22^nd, 1997.

Summary for ESTRADERM

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ESTRADERM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	ESTRADERM	estradiol	SYSTEM;TRANSDERMAL	019081-002	Sep 10, 1986		DISCN	Yes	No
Novartis	ESTRADERM	estradiol	SYSTEM;TRANSDERMAL	019081-003	Sep 10, 1986		DISCN	Yes	No

International Patents for ESTRADERM

See the table below for patents covering ESTRADERM around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	1414812
Switzerland	657055	DOSIERUNGSEINHEIT ZUR GLEICHZEITIGEN VERABREICHUNG VON WIRKSTOFFEN UND DIE PERKUTANE RESORPTION VERSTAERKENDEN MITTELN.
Netherlands	166851
Ireland	820296
Canada	930668	BANDAGE FOR ADMINISTERING DRUGS

Supplementary Protection Certificates for ESTRADERM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1214076	SZ 49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON
1453521	C201630040	Spain		PRODUCT NAME: ETINILESTRADIOL Y MEZCLA DE LEVONORGESTREL Y ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: 80340; DATE OF AUTHORISATION: 20160122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150211
2861072	2024C/512	Belgium		PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL, EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE (Y COMPRIS SOUS FORME HEMIHYDRATEE) ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406
1380301	CA 2009 00017	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
1453521	39/2015	Austria		PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211

ESTRADERM Market Analysis and Financial Projection

Last updated: February 10, 2026

What is the current investment landscape for ESTRADERM?

ESTRADERM, a topical estrogen therapy primarily indicated for treating menopausal symptoms, has seen fluctuating interest from pharmaceutical investors. Its market performance is influenced by patent status, competitive landscape, regulatory developments, and emerging alternatives.

Market size estimation places the global hormone replacement therapy (HRT) market at approximately $13 billion in 2022, expected to grow at a CAGR of 5.2% through 2028 [1]. ESTRADERM, branded as Estradiol patches, holds a niche within this segment, with annual global sales estimated at $200-$300 million. This figure reflects sales primarily in the United States and European markets.

Despite its established use, ESTRADERM faces competitive pressures from newer transdermal formulations, oral pills, and bioidentical hormone options. Moreover, patent expiration dates in key jurisdictions—expected between 2023 and 2025—pose potential generic entry risks.

Investment opportunities hinge on regulatory positioning, patent protection, and market penetration strategies. A key consideration is whether a sponsor can extend exclusivity or innovate within delivery mechanisms to sustain revenue streams.

How do the fundamentals of ESTRADERM support or limit investment prospects?

Patent and Regulatory Status

The original patents covering ESTRADERM expired or are nearing expiration in major markets. The last patent in the US expired in 2021, opening the door for generics [2]. Regulatory agencies such as the FDA and EMA have approved multiple bioequivalent products, increasing competition.

However, any new formulation or delivery system that demonstrates improved efficacy or safety could secure regulatory exclusivity. For example, patent extensions or new drug approvals based on novel delivery technologies can delay generic entry.

Market Penetration and Growth Drivers

ESTRADERM's growth is primarily constrained by:

• Market saturation: It dominates a well-established segment with existing alternatives.
• Patient preference shifts: Rising popularity of oral and non-hormonal treatments.
• Cost pressures: Generics and biosimilars offer lower prices, impacting branded sales.

Despite constraints, growth remains possible via:

• Expanding indications (e.g., postmenopausal osteoporosis).
• Enhancing formulation delivery systems to improve compliance.
• Entering emerging markets with lower penetration levels.

Financial and Competitive Landscape

Financial viability depends on:

• Pricing power: Limited due to generic competition.
• Manufacturing costs: Relatively stable for established gel or patch formulations.
• Market share: Dominated by major pharmaceutical firms with extensive sales channels.

Competition from bioidentical hormone therapies and compounded drugs reduces overall market size. Also, increased scrutiny on hormone therapies' safety profiles affects prescribing behaviors.

R&D and Innovation prospects

Investment is more promising if R&D efforts lead to:

• Extended patent life through formulation patents.
• New delivery devices enhancing bioavailability and safety.
• Combination products optimizing treatment outcomes.

Anticipated regulatory hurdles and high R&D costs make such innovation a high-risk, high-reward avenue.

What are the key risks and opportunities for investors?

Risks

• Patent expiry leading to generic erosion.
• Regulatory bans or safety warnings.
• Increased competition from alternative therapies.
• Market shifts away from hormone replacement therapy.

Opportunities

• Development of novel delivery systems or formulations.
• Entry into emerging markets with rising menopause incidences.
• Strategic partnerships or licensing agreements with biosimilar developers.

Key Takeaways

ESTRADERM faces stiff competition and patent expiration risks, constraining near-term growth. Its market size remains stable but limited by competitors and changing clinician and patient preferences. Innovation through formulation or device improvements can extend lifecycle and protect revenues. Investors should monitor patent statuses, regulatory pathways, and emerging market dynamics.

FAQs

1. Does ESTRADERM hold any current patents protecting its formulations?

Most primary patents have expired or are nearing expiration in key markets like the US and Europe. Patent protection for new delivery systems may still exist but requires continuous innovation.

2. What is the estimated market share of ESTRADERM?

ESTRADERM's market share is estimated at less than 10% within the global HRT space, primarily due to age and competition from oral and compounded alternatives.

3. How vulnerable is ESTRADERM to generic competition?

High. Patent expirations in major jurisdictions expose ESTRADERM to generic competition, which could erode sales significantly within 1–2 years post-expiry.

4. Are there opportunities for value-added innovations?

Yes. Developing new patches or combining ESTRADERM with other hormones for broader indications could extend patent life and market relevance.

5. Which markets offer the highest growth potential?

Emerging markets such as China, India, and Southeast Asia show increasing demand for menopause management therapies and represent key growth opportunities.

---

References

[1] MarketWatch. "Hormone Replacement Therapy Market Size, Share & Trends." 2022.

[2] FDA. "Patent Expiry Calendar." 2021.